middle.news
Cambium Bio Secures A$2.17M to Advance Elate Ocular® Phase 3 Trials
1:04am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
Cambium Bio Secures A$2.17M to Advance Elate Ocular® Phase 3 Trials
1:04am on Saturday 30th of August, 2025 AEST
Key Points
Placement increased to A$2.17 million from A$2.12 million
Issue price remains steady at A$0.4637 per share
Key investors include Chen Tsung Chi and Chun Yi Wu
Shares subscribed by two directors pending shareholder approval
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cambium Bio (ASX:CMB)
OPEN ARTICLE